A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Trial Profile

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ECHELON-1
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 27 Jul 2017 According to a Seattle Genetics media release, company plans to submit data from this trial to Health Canada for approval of ADCETRIS in frontline advanced classical Hodgkin lymphoma, Takeda plans to submit the results to regulatory authorities in its territory.
    • 25 Jul 2017 According to a Seattle Genetics media release, Company plans to submit a supplemental BLA to the FDA for ADCETRIS in frontline Hodgkin lymphoma based on the data from this study.
    • 26 Jun 2017 According to a Takeda media release, an abstract will be submitted for data presentation from this trial at the American Society of Hematology (ASH) annual meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top